Background-Previous studies in animal models of angioplasty have suggested a role in neointimal hyperplasia for endothelins (ETs), potent vasoconstricting peptides that also exert growth-promoting effects. The present studies were undertaken to test the hypothesis that endothelin receptor blockade can reduce neointimal thickening in injured porcine coronary arteries. Methods and Results-An ET A /ET B antagonist, L-749,329, was evaluated as an inhibitor of intimal thickening in a porcine balloon/stent model of coronary artery injury. L-749,329 competitively inhibited [ 125 I]ET-1 binding to porcine ET A (IC 50 Ϸ0.3 nmol/L) or ET B (IC 50 Ϸ20 nmol/L) receptors and inhibited ET-1-stimulated signaling in cell culture. In anesthetized pigs, big ET-1-stimulated increases in systemic blood pressure were totally inhibited after intravenous infusion of L-749,329 (Ն0.2 mg · kg Ϫ1 · h Ϫ1 ). In vascular injury studies, pigs were treated with vehicle or L-749,329
T he endothelins constitute a family of endotheliumderived polypeptides that are among the most potent vasoconstrictors known. 1, 2 The major endothelin receptor subtypes (ET A and ET B ) are expressed in vascular smooth muscle, where they mediate vasoconstriction, 3 whereas the ET B subtype on endothelial cells is believed to mediate vasorelaxation. 4 These receptors have become targets for the development of agents to treat hypertension, myocardial ischemia, and congestive heart failure. 5 In addition to their acute effects on vascular tone, endothelins are recognized to exert growth-promoting effects, 6 a response associated with activation of the ET A receptor. 7 Endothelin receptors are elevated in atherosclerotic coronary arteries. 8 Elevated plasma levels of immunoreactive ET-1 or its immediate precursor, big ET-1, have been detected in patients with angina pectoris 9 and acute myocardial infarc-tion. 10 In addition, elevated endothelins have been observed acutely after cardiac catheterization 11 or PTCA. 12 The clinical results, together with in vitro data, 13 have suggested that endothelins may be involved in atherosclerosis, vascular hypertrophy, and restenosis after angioplasty. 14 Balloon denudation of rabbit carotid arteries was associated with prolonged elevation in immunoreactive ET-1 and induction of ET B binding activity localized to the neointima. 15, 16 In rat carotid arteries, mRNAs for endothelin precursors, endothelin-converting enzyme-1, and both ET A and ET B receptors were induced by balloon injury. 17 Moreover, infusion of ET-1 was found to potentiate carotid neointimal formation provoked by balloon angioplasty in rats. 18, 19 In inhibitor studies, long-term administration of antagonists with activity toward both ET A and ET B receptors markedly reduced neointimal formation in balloon-injured rat carotid arter-ies. 20, 21 The ET A -selective antagonist BQ-123 was ineffective in rat 20 and rabbit 15 carotid artery studies, suggesting a predominant role for the ET B receptor in lesion development. In contrast to these findings, several ET A -selective agents have been reported to inhibit neointimal thickening in rat and porcine vascular injury studies. [22] [23] [24] [25] Thus, results reported to date do not clearly indicate whether the ET A or ET B receptor subtype is of principal importance in the response to injury. In the present studies, we evaluated a potent, mixed ET A /ET B endothelin receptor antagonist for its ability to inhibit intimal thickening in a porcine coronary artery model of vascular restenosis. 26 
Methods

Endothelin Receptor Ligands
Porcine sequence ET-1 and big ET-1 (Peptide Institute), BQ-123 (Bachem), and sarafotoxin S6C (Peninsula) were prepared as recommended by their respective vendors. For PTCA studies, L-749,329 (racemic L-754,142 27 ) was prepared at 50 mg/mL in 0.9% saline. All agents were filter sterilized before administration.
Receptor Binding Assays
Levels of L-749,329 in pig plasma were estimated by radioreceptor assays with rat aortic smooth muscle cell (SMC) cultures 28 I]ET-1, and data analysis were performed as described previously. 28 A similar procedure was used for assays of endothelin receptor antagonist potency in pig SMC and LLC-PK1 cells, 29 except that binding incubations contained 0.01% BSA and no plasma or heparin. Specific binding was defined as total binding minus binding occurring in the presence of 1 mol/L ET-1.
Measurement of Inositol Phosphate Production
Confluent cultures of pig coronary artery SMCs in 24-well dishes were labeled for 48 hours at 37°with 3 Ci of [ 3 H]myoinositol (Amersham; 18.3 Ci/mmol) in inositol-free DMEM (Irvine), 0.5% fetal bovine serum. Cells were washed with DMEM containing 1 mg/mL myoinositol, 10 mmol/L LiCl, and 0.1% BSA and stimulated with ET-1 in the presence or absence of L-749,329 for 60 minutes at 37°C. [ 3 H]Inositol phosphates were measured as described previously. 30 
Instrumentation
All animal studies were performed according to procedures approved by the Merck-West Point Institutional Animal Care and Use Committee. Juvenile male or female Yorkshire pigs (weight Ϸ30 kg) were catheterized for compound infusion and blood sampling as described previously. 28 When required for blood pressure monitoring, a vascular access port was placed in the common carotid artery and secured subcutaneously in the right lateral cervical area. Arterial pressure in animals under isoflurane anesthesia was measured by DTX pressure transducer systems with ECG monitoring. Animals were allowed to recover in their home cages and were observed until stable.
Angioplasty Studies
Animals were premedicated with 650 mg of aspirin (24 hours before angioplasty), 30 mg of nifedipine (2 hours before), and 10 000 U of heparin (immediately before). After 2 days of pretreatment with vehicle (0.9% saline) or L-749,329 (50 mg/mL; 1 mg · kg Ϫ1 · h Ϫ1 ), animals were reanesthetized and subjected to angioplasty of the left anterior descending, left circumflex, and/or right coronary arteries under fluoroscopic imaging. 28 The balloon was inflated to 8 atm for 15 seconds to deploy the coiled, tantalum wire stent, resulting in a 1.2-to 1.4-fold ratio of balloon diameter to initial vessel diameter. After intravenous administration of 1 g of cefoxitin, animals were allowed to recover in their home cages and were maintained for 28 days after angioplasty with constant intravenous infusion of vehicle or test compound. Jugular catheters were flushed aseptically with saline 3 times per week and locked with 50% glucose/heparin. Blood samples were drawn weekly for measurement of plasma drug levels. Ampicillin (500 mg PO) was given daily.
Analysis of Neointimal Thickening
Animals were euthanatized with pentobarbital (60 mg/kg IV) on day 28 after angioplasty. Formalin-fixed coronary arterial segments containing the expanded stent were excised and processed for 5-m cross-sectioning and hematoxylin/eosin and elastin-van Gieson staining as described previously. 26, 28 Sections from each vessel were scored for degree of injury and neointimal thickness using the section showing the most severe injury. The measurements for each vessel were averaged to produce a single data point. Luminal areas and areas circumscribed by internal and external elastic laminae also were measured at the site of injury. Preangioplasty lumen size was estimated by measuring the uninvolved luminal area Ϸ5 mm distal to the site of balloon/stent deployment.
All values reported are estimates of the meanϮSE. For neointimal thickness, injury score, and luminal areas, estimates were calculated by maximum likelihood methodology and a linear mixed-effects model with a random effect for each pig. Separate analyses were performed on data from the L-749,329 -treated and control pigs. Neointimal thickness was fit on the logarithmic scale; all other variables were fit with the scale on which they were measured. Comparisons of injury score and external elastic lamina areas for the 2 treatment groups were made by a maximum likelihood ratio test; probability values for these comparisons were 2-sided. Comparisons of the treatment means that were adjusted for injury score (neointimal thickness and luminal areas) were made with linear regression and the jackknife procedure 28 to estimate standard errors. Specifically, after we checked for parallelism, log(neointimal thickness) or log(luminal area) was regressed on injury score for the injured vessels of antagonist-treated and control pigs. Regression lines with equal slopes were fit for the treated and control pigs, allowing the difference between treatment and control to be measured by the difference in intercepts. By this method, the comparisons were on a "per pig" basis. Probability values reported for these comparisons are 1-sided.
Results
Potency of L-749,329 Toward Porcine ET-1 Receptors
L-749,329 is the racemic form of the nonpeptide endothelin receptor antagonist L-754,142, which exhibits potent activity toward both the ET A (K i ϭ0.062 nmol/L for the cloned human receptor) and ET B (K i ϭ2.25 nmol/L) subtypes. 27 The ability of L-749,329 to interact with porcine endothelin receptors was confirmed in binding studies with porcine coronary artery SMCs and LLC-PK1 porcine kidney epithelial cells ( Figure 1 ). In the presence of 50 pmol/L [ 125 I]ET-1 radioligand, L-749,329 blocked ET-1 binding with an IC 50 of Ϸ0.3 nmol/L. [ 125 I]ET-1 binding to porcine SMCs was totally inhibited by the ET A -selective antagonist BQ-123 (IC 50 Ϸ1 nmol/L) but not appreciably by the ET B -selective ligand sarafotoxin 6-C, indicating that the ET A receptor subtype is expressed predominantly in these cells ( Figure 1A ). In cultures of LLC-PK1 cells, which principally express the ET B subtype, 29 L-749,329 inhibited [ 125 I]ET-1 binding with an IC 50 of Ϸ20 nmol/L ( Figure 1B ). The predominance of ET B sites on these cells is confirmed by the high competitive potency of sarafotoxin 6-C (IC 50 Ϸ1 nmol/L) and the relatively low potency of BQ-123. Thus, relative potencies of L-749,329 toward porcine ET A and ET B receptors in intact-cell binding assays (ET B /ET A IC 50 ratio Ϸ65) are comparable to that for L-754,142 toward the human receptor forms (K i ratio Ϸ35). 27
Inhibition of ET-1 Signaling by L-749,329
Pig coronary artery SMCs prelabeled with [ 3 H]myoinositol were stimulated with ET-1 in the presence or absence of L-749,329, and total cellular [ 3 H]inositol phosphates were measured. In these experiments, ET-1 stimulated [ 3 H]inositol phosphate production by 2.5-to 3-fold, with an EC 50 of Ϸ0.18 nmol/L (Figure 2 ). In the presence of 100 nmol/L L-749,329, the ET-1 dose-response curve was shifted rightward by Ϸ2.4 log units without a reduction in the maximal response to ET-1, consistent with a competitive inhibition of the ET A receptor.
Dose-Finding Experiments
Pressor responses to ET-1 or its biosynthetic precursor, big ET-1, were measured in anesthetized animals before and after a series of intravenous infusions of L-749,329. ET-1 (0.25 to 0.5 nmol/kg) produced rapid and prolonged increases in mean arterial pressure (MAP); at lower doses of ET-1 (0.1 to 0.2 nmol/kg), a transient depressor phase of response was noted 1 to 3 minutes after ET-1 administration (not shown). Depressor responses to ET-1 have been linked to ET Bmediated vasodilation in other species. 4 Bolus doses of L-749,329 (1 to 10 mg/kg) were associated with decreases in both the magnitude and duration of MAP increases stimulated by ET-1. In separate studies, doses of ET-1 (0.25 nmol/kg) and big ET-1 (0.5 nmol/kg) that yielded similar maximum ⌬MAP responses in the pig (30 to 40 mm Hg) were determined empirically (Figure 3 , "Control"). Consistent with previous reports, 31 big ET-1 produced an increase in MAP that was slower in onset and relatively prolonged compared with that stimulated by ET-1. In the experiment shown, constant intravenous infusion of L-749,329 at 1.0 mg · kg Ϫ1 · h Ϫ1 for 24 hours produced 78% inhibition of the pressor response to ET-1 and total inhibition of the response to big For measurement of control pressor responses, the animal was anesthetized and challenged with 0.25 nmol/kg ET-1 or 0.5 nmol/kg porcine big ET-1 (pBig ET-1); MAP was recorded at intervals of 0.5 to 1 minute over a 90-minute period. To measure pressor inhibition, L-749,329 was administered at 1 mg · kg Ϫ1 · h Ϫ1 for 24 hours, and the animal was reanesthetized for pressor challenge.
Huckle et al Effects of L-749,329 on Porcine Restenosis
ET-1 (Figure 3 ). This degree of inhibition of the response to ET-1 was not exceeded even when L-749,329 infusion was increased to 5 mg · kg Ϫ1 · h Ϫ1 , whereas rates lower than 0.2 mg · kg Ϫ1 · h Ϫ1 were associated with diminished inhibition of both the ET-1 and big ET-1 responses. The rates of infusion associated with maximal inhibition of ET-1 and big ET-1 pressor responses gave rise to plasma levels of L-749,329Ն340 nmol/L. On the basis of these results, a dose of 1 mg · kg Ϫ1 · h Ϫ1 was chosen for the PTCA studies, with a target plasma L-749,329 concentration of Ն400 nmol/L.
Angioplasty Studies
Seven pigs each were assigned to receive vehicle or L-749,329 infusion beginning 2 days before PTCA. Balloon/ stent angioplasty was performed on a total of 21 vessels in the vehicle group and 20 vessels in the L-749,329 -treated group.
In the antagonist-treated animals, mean plasma levels of L-749,329 were 1300Ϯ540 nmol/L on the day of angioplasty and were maintained between 1210 and 1670 nmol/L throughout the 28-day study period. These levels are well above those determined independently to be associated with maximal blockade of pressor responses to endothelins. At day 28 after angioplasty, animals were euthanatized, and hearts were removed for histomorphometric analysis. Elastin-van Gieson-stained sections from each injured vessel were examined by light microscopy for determination of injury score and neointimal thickness (Figure 4 ). Mean injury scores did not differ between the 2 groups (Pϭ0.76; Table) .
Treatment with L-749,329 was associated with a 9.0% decrease in mean neointimal thickness when adjusted for injury score, but this effect was not statistically significant (Pϭ0.13) ( Figure 5 ). Mean vessel luminal area at the site of angioplasty (adjusted for injury score) was increased by 18% in the L-749,329 -treated animals compared with the vehicle group; again, this effect was not statistically significant (Pϭ0.06). When the net change in luminal area was calculated for each vessel (luminal area at the site of injury minus the preinjury luminal area approximated as the uninvolved luminal area measured 5 mm distal to the site of angioplasty), the increase associated with L-749,329 treatment dropped to 7.0% (Pϭ0.36). Thus, the small reduction in neointimal thickness (9.0%) associated with L-749,329 treatment was accompanied by a small increase in luminal area (7.0%). The mean areas circumscribed by the internal elastic laminae in the 2 treatment groups were very similar (Table) , consistent with the approximately reciprocating changes in luminal area and neointimal thickness noted above. Mean areas circumscribed by the external elastic lamina in the 2 groups also were similar.
Discussion
Endothelin receptor antagonists have been used to probe the involvement of endothelins in postangioplasty neointimal hyperplasia. Studies in animal models of vascular injury have suggested a role for endothelins in neointimal formation but have produced conflicting results with respect to the endo- thelin receptor subtype(s) involved. In the present studies, we evaluated a mixed ET A /ET B endothelin receptor antagonist, L-749,329, for its ability to inhibit intimal thickening in a porcine balloon/stent injury model. L-749,329 competitively inhibited [ 125 I]ET-1 binding to ET A (IC 50 Ϸ0.3 nmol/L) or ET B (IC 50 Ϸ20 nmol/L) receptors on cultured porcine cells. L-749,329 competitively inhibited ET A -mediated signaling in vitro, as measured by ET-1-stimulated phosphoinositide metabolism in pig coronary artery SMCs. In anesthetized pigs, increases in systemic blood pressure in response to big ET-1 were totally abolished after intravenous infusion of L-749,329 (Ն0.2 mg · kg Ϫ1 · h Ϫ1 ). In conscious pigs, chronic L-749,329 treatment (1 mg · kg Ϫ1 · h Ϫ1 ) was associated with a median decrease in MAP of 22.1 mm Hg and an increase in heart rate of 15 bpm (W.R.H., R.G.J., unpublished data, 1998). In angioplasty studies, L-749,329 was administered by chronic intravenous infusion beginning 2 days before balloon/stent injury and continuing until animals were killed (day 28 after angioplasty). Plasma levels of the antagonist in L-749,329 -treated animals were considerably in excess of levels associated with maximal pressor blockade, as well as the IC 50 values determined in vitro. Mean neointimal thickness in the L-749,329 -treated group was reduced by 9.0% compared with vehicle-treated controls, but this effect was not statistically significant (Pϭ0.13).
Our results using a mixed ET A /ET B endothelin receptor antagonist differ from previous findings obtained with an ET A -selective agent in the same model system. 24 Several factors may contribute to this difference. Although the present results suggest that blockade of both ET A and ET B receptors is not an effective means of reducing neointimal thickening in pig coronary artery, the value of ET A versus ET B selectivity remains unresolved. 20, 22 It is possible, for example, that preservation of vasodilatation mediated by ET B might be protective after vascular injury in the pig, such that ET B blockade might exacerbate luminal loss. Another difference between the 2 studies is route of administration (intravenous and oral), which may have produced a distribution of inhibitor that favored efficacy in the prior studies. In addition, different methods of statistical analysis were applied in the 2 studies. Finally, the mean injury scores in the present study (2.07 and 2.13 for the vehicle and L-749,329 -treated groups, respectively) were uniformly higher than those measured in the previous study (ranging from 1.73 to 1.94 24 ); measurements for both studies were made by the same core investigators at the Mayo Clinic. Thus, the absence of significant efficacy in the present study may stem from our relatively higher degree of vessel injury. This idea is supported by the observation in the previous study that the intermediate dose of ET A -selective agent was ineffective against a mean injury score of 1.94, whereas a lower dose was effective against a lower mean injury score of 1.73. Similarly, the ET A -selective antagonist LU 135252 recently was reported to significantly reduce the neointimal:medial ratio in a porcine balloon-only injury model 32 ; balloon expansion alone typically imparts an injury no more severe than medial dissection (ie, equivalent to injury score 2), whereas stent deployment can rupture the Statistical analysis was performed as described in Methods. Values given are meanϮSE for injury score, luminal areas, and areas circumscribed by the internal elastic lamina (IEL) and external elastic lamina (EEL) and geometric meanϮSE for neointimal thicknesses. Percent changes in neointimal thickness and luminal areas and their associated 1-sided P values are from the analyses that adjust neointimal thickness or luminal area using the injury score. 
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Effects of L-749,329 on Porcine Restenosis external elastic lamina as well (injury score 3). The mean injury scores Ͼ2 in the present study reflect the greater incidence of external elastic lamina disruption. Several limitations to the present studies should be noted. The animals used likely were normolipidemic, and the vessels targeted were not previously injured. Consequently, we cannot infer the effects of L-749,329 in atherosclerotic vessels. However, all of the prior studies mentioned above likewise were conducted in nondiseased arteries, and effects of endothelin antagonists still were manifest. Second, treatment with endothelin receptor antagonists is recognized to increase endothelin receptor levels in culture 33 and increase circulating endothelin levels in vivo. 34 Because we did not measure endothelin levels or monitor pressor inhibition throughout the 30-day study, it might be argued that compensatory changes in endothelin or receptor expression rendered L-749,329 less effective. This argument is countered by the observation that mean L-749,329 plasma levels were maintained at Ͼ1000 nmol/L, ie, Ͼ50-fold excess over the IC 50 s for ET-1 binding. Third, we cannot exclude the possibility that adequate concentrations of L-749,329 did not reach sites critical for reducing neointimal hyperplasia, although the inhibitor clearly had access to sites involved in endothelin pressor responses.
A variety of studies have documented the activities of endothelins and their receptors in normal and injured porcine coronary arteries. Endothelin-stimulated contraction of isolated strips of pig coronary arteries is composed of both ET A antagonist-sensitive and -insensitive components, suggesting that both ET A and ET B receptors can mediate constriction of these vessels. 35, 36 In addition, ET B receptors may be heterogeneous in pig coronary artery. 37 Net release of ET-1 from pig coronary arteries has been detected after short-term vessel occlusion 38 and in thrombosis/thrombolysis models. 39 ET immunoreactivity and increased densities of presumptive ET A and ET B receptors have been detected at sites of experimental angioplasty in pigs. 24, 32, 40 The consequences of endothelin receptor blockade at injury sites may be determined by the balance between the benefit of inhibiting ET A /ET B -mediated growth promotion or vasoconstriction and the penalty of inhibiting vasorelaxation. The relative influence of these factors and therefore the utility of endothelin antagonists for controlling neointimal hyperplasia may vary with species, vessel types, and the nature and severity of injury imparted. Further studies using subtype-selective agents in coronary injury models with atherosclerotic subjects, as well as results from clinical studies, will help resolve these issues.
